Short answer
Viridian Therapeutics, Inc.\DE (VRDN) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Viridian’s press release reports financial results for the quarter ended September 30, 2026.
Viridian Therapeutics, Inc.\DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Viridian’s press release reports financial results for the quarter ended September 30, 2026
- Investor focus: quarterly cash position, operating expenses, pipeline progress, and guidance in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Lumvoa Q3 net product revenue $24.7M, with more than 100 patients on therapy, establishing initial commercial traction in TED
- Permanent CMS J-code J3242 effective January 1, 2027, potentially supporting reimbursement and broader Lumvoa adoption
- Q3 net loss $101.2M versus $34.6M, as SG&A increased to $57.6M from $24.3M for commercial launch investment
- Cash, equivalents, and marketable securities $955.2M, providing funding runway for current plans through anticipated profitability
- Key catalysts: VRDN-008 phase 1 data in Q4 2026, VRDN-292 phase 1 initiation in Q4 2026, elegrobart BLA targeted for Q1 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Viridian Therapeutics, Inc.\DE 8-K filings
Get the next VRDN 8-K as it lands
Follow VRDN for push alerts, or ask the research agent what this filing means.